Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-15

Study Completion Date

2024-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with a highly variable presentation and course. It can affect virtually every organ of the body and many symptoms may be observed. Skin, musculoskeletal, hematologic, and serological involvement are most commonly observed. Some patients show predominately hematologic, renal, or central nervous system manifestations.

Studies have reported that juvenile-onset SLE patients tend to have a more aggressive presentation and course, with higher rates of organ involvement and lower life expectancy than adult-onset SLE patients. Late-onset SLE patients tend to have a more insidious onset of disease and tend to have less major organ involvement and more benign disease course. However, they have a poorer prognosis than patients who developed SLE before the age of 50 years, because of the generally higher frequency of comorbid diseases and higher organ damage, due to aging and longer exposure to ''classical'' vascular risk factors.

Aims of the Study:

To compare clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients in our hospital.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus.

NCT06294483

Systemic Lupus Erythematosus

ENROLLING_BY_INVITATION

Study of Systemic Lupus Erythematosus

NCT00001372

Systemic Lupus Erythematosus

RECRUITING

Systemic Lupus Erythematosus

NCT05984316

System; Lupus Erythematosus Cognition Disorder Autoimmune

UNKNOWN NA

Anemia in Systemic Lupus Erythematosus Specially Refractory Type

NCT06210295

Refractory Anemia in Systemic Lupus Erythematosis

NOT_YET_RECRUITING

Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.

NCT02891213

Lupus Erythematosus

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Methods:

All patients will be subjected to the following:

1. Thorough medical history of the patients
2. Full clinical examination including:

1. General examination and vital signs.
2. Complete rheumatological examination.
3. SLE disease activity index SLEDAI (ref).
4. SLICC damage index (ref).
3. Routine investigations (complete blood picture, erythrocyte sedimentation rate and liver functions).
4. Renal investigations:

1. Kidney functions
2. Urine analysis
3. 24 hours protein in urine and/or A/C ratio
4. Renal biopsy if indicated.
5. ANA test.
6. ANA profile for the most common 19 autoantibodies by immunoblot.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Lupus Erythematosus (SLE)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients

All patients will be subjected to the following:

1. Thorough medical history of the patients
2. Full clinical examination including:

1. General examination and vital signs.
2. Complete rheumatological examination.
3. SLE disease activity index SLEDAI (ref).
4. SLICC( Systemic Lupus International Collaborating Clinics) damage index (ref).
3. Routine investigations (complete blood picture, erythrocyte sedimentation rate and liver functions).
4. Renal investigations:

1. Kidney functions
2. Urine analysis
3. 24 hours protein in urine and/or A/C ratio
4. Renal biopsy if indicated.
5. ANA (Antinuclear Antibodies)test.
6. ANA profile for the most common 19 autoantibodies by immunoblot.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients diagnosed as SLE( Systemic lupus erythematosus )according to EULAR / ACE (European League Against Rheumatism /American College of Rheumatology )
2. Age juvenile SLE ( Systemic lupus erythematosus )was defined as a diagnosis below the age of 18 years, and those diagnosed between 19 and 50 years of age were classified as adult SLE ( Systemic lupus erythematosus ), late onset SLE was defined as a diagnosis at more than 50 years of age).
3. Patients with a disease duration of more than 6 months

Exclusion Criteria

1. Patients with had other autoimmune diseases, such as rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease , overlap syndrome or primary Sjogren's syndrome ,but not secondary Sjogren's syndrome or secondary antiphospholipid syndrome .
2. Patients who are not willing to be involved in the study

Minimum Eligible Age

6 Months

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No